Stockholm, November 2, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drug molecules – angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for the third quarter 2023. Read more…
Each year, Rare Disease Day aims to raise awareness of rare diseases and encourage positive change to patients’ lives. A disease is considered rare when it affects fewer than 1 in 2,000 people and there are 300 million people with rare diseases across the world.1 On Rare Disease Day 2023, we want to celebrate the […]
The award highlights significant company growth and advancement in the field of RNA modifying enzymes (RME) as STORM aims to become the global leader in the field of RME.
